Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 2
1996 4
1997 2
1998 4
1999 3
2000 2
2001 3
2002 16
2003 46
2004 113
2005 151
2006 201
2007 255
2008 304
2009 284
2010 287
2011 325
2012 304
2013 315
2014 305
2015 318
2016 351
2017 355
2018 358
2019 341
2020 302
2021 369
2022 347
2023 341
2024 286

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,610 results

Results by year

Filters applied: . Clear all
Page 1
New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression.
Orzelska-Górka J, Mikulska J, Wiszniewska A, Biała G. Orzelska-Górka J, et al. Int J Mol Sci. 2022 Sep 13;23(18):10624. doi: 10.3390/ijms231810624. Int J Mol Sci. 2022. PMID: 36142523 Free PMC article. Review.
The purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazole, cariprazine, lurasidone, asenapine, brexpiprazole, lumateperone, pimavanserin) in treatment of schizophrenia and depression. ...
The purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazo
A safety evaluation of aripiprazole in the treatment of schizophrenia.
Preda A, Shapiro BB. Preda A, et al. Expert Opin Drug Saf. 2020 Dec;19(12):1529-1538. doi: 10.1080/14740338.2020.1832990. Epub 2020 Oct 16. Expert Opin Drug Saf. 2020. PMID: 33064050 Review.
AREAS COVERED: We review short-and-long-term clinical trials, meta-analyses of clinical trials and product information pertaining to the safety and efficacy of aripiprazole in adults with schizophrenia. Formulations of aripiprazole reviewed include oral aripipraz
AREAS COVERED: We review short-and-long-term clinical trials, meta-analyses of clinical trials and product information pertaining to the saf …
Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.
Lenze EJ, Mulsant BH, Roose SP, Lavretsky H, Reynolds CF 3rd, Blumberger DM, Brown PJ, Cristancho P, Flint AJ, Gebara MA, Gettinger TR, Lenard E, Miller JP, Nicol GE, Oughli HA, Pham VT, Rollman BL, Yang L, Karp JF. Lenze EJ, et al. N Engl J Med. 2023 Mar 23;388(12):1067-1079. doi: 10.1056/NEJMoa2204462. Epub 2023 Mar 3. N Engl J Med. 2023. PMID: 36867173 Free PMC article. Clinical Trial.
RESULTS: In step 1, a total of 619 patients were enrolled; 211 were assigned to aripiprazole augmentation, 206 to bupropion augmentation, and 202 to a switch to bupropion. ...Remission occurred in 28.9% of patients in the aripiprazole-augmentation group, 28.2% in th …
RESULTS: In step 1, a total of 619 patients were enrolled; 211 were assigned to aripiprazole augmentation, 206 to bupropion augmentat …
Risperidone and aripiprazole for autism spectrum disorder in children: an overview of systematic reviews.
Fieiras C, Chen MH, Escobar Liquitay CM, Meza N, Rojas V, Franco JVA, Madrid E. Fieiras C, et al. BMJ Evid Based Med. 2023 Feb;28(1):7-14. doi: 10.1136/bmjebm-2021-111804. Epub 2022 Jan 31. BMJ Evid Based Med. 2023. PMID: 35101925 Review.
OBJECTIVES: To assess the effectiveness and safety of risperidone and aripiprazole in children with autism spectrum disorder (ASD). DESIGN AND SETTING: Overview of systematic reviews (SRs). ...CONCLUSIONS: We found that aripiprazole and risperidone probably reduce s …
OBJECTIVES: To assess the effectiveness and safety of risperidone and aripiprazole in children with autism spectrum disorder (ASD). D …
Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. Tiihonen J, et al. JAMA Psychiatry. 2019 May 1;76(5):499-507. doi: 10.1001/jamapsychiatry.2018.4320. JAMA Psychiatry. 2019. PMID: 30785608 Free PMC article.
Among patients with their first episode of schizophrenia, these differences between clozapine plus aripiprazole vs clozapine monotherapy were greater (difference, 22%; HR, 0.78; 95% CI, 0.63-0.96 in the analysis including all polypharmacy periods, and difference, 23%; HR, …
Among patients with their first episode of schizophrenia, these differences between clozapine plus aripiprazole vs clozapine monother …
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi JFC, Ferreira FR, Silva-Amaral D, Lima DA, Hallak JEC, Zuardi AW, Del-Bel EA, Guimarães FS, Costa KCM, Campos AC, Crippa ACS, Crippa JAS. Pedrazzi JFC, et al. Psychopharmacology (Berl). 2022 Sep;239(9):2713-2734. doi: 10.1007/s00213-022-06196-4. Epub 2022 Jul 29. Psychopharmacology (Berl). 2022. PMID: 35904579 Review.
The treatment of ASD has low efficacy, possibly because it has a heterogeneous nature, and its neurobiological basis is not clearly understood. Drugs such as risperidone and aripiprazole are the only two drugs available that are recognized by the Food and Drug Administrati …
The treatment of ASD has low efficacy, possibly because it has a heterogeneous nature, and its neurobiological basis is not clearly understo …
Cannabinoid treatment for the symptoms of autism spectrum disorder.
Aran A, Cayam Rand D. Aran A, et al. Expert Opin Emerg Drugs. 2024 Mar;29(1):65-79. doi: 10.1080/14728214.2024.2306290. Epub 2024 Jan 23. Expert Opin Emerg Drugs. 2024. PMID: 38226593 Review.
Currently, no established pharmacological treatment exists for core ASD symptoms. Risperidone and aripiprazole are used to manage associated irritability, but their effectiveness is limited and adverse events are common. ...
Currently, no established pharmacological treatment exists for core ASD symptoms. Risperidone and aripiprazole are used to manage ass …
Aripiprazole.
Prommer E. Prommer E. Am J Hosp Palliat Care. 2017 Mar;34(2):180-185. doi: 10.1177/1049909115612800. Epub 2016 Jul 10. Am J Hosp Palliat Care. 2017. PMID: 26589880 Review.
Third-generation atypical antipsychotic drugs have emerged as a potential choice for delirium management. Aripiprazole is a third-generation antipsychotic with a dopamine receptor-binding profile distinct from other second-generation antipsychotics. Aripiprazole act …
Third-generation atypical antipsychotic drugs have emerged as a potential choice for delirium management. Aripiprazole is a third-gen …
Aripiprazole-Associated Oligospermia.
Garip B, Oğur B, Uzun O. Garip B, et al. Am J Ther. 2022 Nov-Dec 01;29(6):e725-e726. doi: 10.1097/MJT.0000000000001246. Epub 2020 Oct 1. Am J Ther. 2022. PMID: 33021544 No abstract available.
Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial.
Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, Robinson DG. Kane JM, et al. JAMA Psychiatry. 2020 Dec 1;77(12):1217-1224. doi: 10.1001/jamapsychiatry.2020.2076. JAMA Psychiatry. 2020. PMID: 32667636 Free PMC article. Clinical Trial.
Site randomization assigned 19 clinics to encourage treatment with long-acting aripiprazole monohydrate (aripiprazole once monthly [AOM] condition) and 20 to provide treatment as usual (clinician's choice [CC] condition). ...INTERVENTIONS: There were no restrictions …
Site randomization assigned 19 clinics to encourage treatment with long-acting aripiprazole monohydrate (aripiprazole once mon …
5,610 results